Rephonic
Artwork for Decera Clinical Education Oncology Podcast

Decera Clinical Education Oncology Podcast

Decera Clinical Education
Non-Small Cell Lung Cancer
BTK Inhibitors
Chronic Lymphocytic Leukemia
Multiple Myeloma
CAR T-Cell Therapy
Bispecific Antibodies
Clinical Trials
Biomarker Testing
Breast Cancer
CDK4/6 Inhibitors
Ovarian Cancer
Immunotherapy
Her2-Positive Metastatic Breast Cancer
ROS1
Polycythemia Vera
Essential Thrombocythemia
Mantle Cell Lymphoma
Venetoclax
Endometrial Cancer
NCCN Guidelines

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

PublishesDailyEpisodes265Founded6 years ago
Number of ListenersCategories
CoursesEducationHealth & FitnessMedicine

Listen to this Podcast

Artwork for Decera Clinical Education Oncology Podcast

Latest Episodes

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including:

• Treatment for underserved populations

• Navigating REMS for novel therapeutics

• Clini... more

YouTube

In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including:

• The recent FDA approval of iberdomide

• Mechanism of ac... more

YouTube

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection acr... more

YouTube

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert dis... more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc Docs
Two Onc DocsSam and Karine
JAMA Medical News
JAMA Medical NewsJAMA Network
OncLive® On Air
OncLive® On AirOncLive® On Air
NEJM This Week
NEJM This WeekNEJM Group

Recent Guests

Daniela Roman
Oncologist from Allegheny Health Network
Allegheny Health Network
Episode: Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer
Jordan Hill
Oncologist from West Virginia University Cancer Institute
West Virginia University Cancer Institute
Episode: Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer
Emanuela Palmerini
TGCT expert, Sylvester Comprehensive Cancer Center
Sylvester Comprehensive Cancer Center
Episode: TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care
William Tack
TGCT expert, Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Episode: TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care
James Davis
PharmD BCOP from the MUSC College of Pharmacy
MUSC College of Pharmacy
Episode: Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
Kelley L. Julian
PharmD BCOP from the Huntsman Cancer Institute
Huntsman Cancer Institute
Episode: Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
Gilles Salles
Lymphoma Service Chief at Memorial Sloan Kettering Cancer Center, affiliated with Weill Cornell University
Memorial Sloan Kettering Cancer Center / Weill Cornell University
Episode: New and Emerging Targeted Therapies for Patients With DLBCL
Pier Luigi Zinzani
Professor of Hematology, Director of the Institute of Hematology Seràgnoli
University of Bologna
Episode: New and Emerging Targeted Therapies for Patients With DLBCL
Shanu Modi
Breast medical oncologist, Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Episode: Changing the Paradigm in HER2-Positive Early Breast Cancer

Hosts

Gervais Constanze
Host of the Decera Clinical Education Oncology Podcast
Sharif Mursalib
Host of Decera Clinical Education Oncology Podcast

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#191
Canada/Education/Courses
Apple Podcasts
#199
Germany/Education/Courses
Apple Podcasts
#12
Argentina/Education/Courses
Apple Podcasts
#75
Sweden/Education/Courses
Apple Podcasts
#97
India/Education/Courses
Apple Podcasts
#112
Ireland/Education/Courses
Apple Podcasts
#113
Taiwan/Education/Courses
Apple Podcasts
#124
Japan/Education/Courses
Apple Podcasts
#137
Hong Kong/Education/Courses
Apple Podcasts
#146
Saudi Arabia/Education/Courses
Apple Podcasts
#159
South Korea/Education/Courses
Apple Podcasts
#180
Netherlands/Education/Courses
Apple Podcasts
#188
Austria/Education/Courses
Apple Podcasts
#196
Israel/Education/Courses
Apple Podcasts
#221
Denmark/Education/Courses
Apple Podcasts
#238
Argentina/Education
Apple Podcasts
#249
New Zealand/Education/Courses

Talking Points

Recent interactions between the hosts and their guests.

TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care
Q: Dr. Palmerini, could you start by telling us a little bit about TGCT and lead into how we treat it?
TGCT is a translocation-driven disease where tumor cells overexpress CSF1, attracting inflammatory cells that drive symptoms. Treatment now ranges from targeted CSF1R inhibitors to traditional surgery, with emphasis on multidisciplinary care and patient-centered goals to optimize function and quality of life.
Changing the Paradigm in HER2-Positive Early Breast Cancer
Q: How should clinicians monitor and manage ILD risk when using TDXD in the neoadjuvant/adjuvant setting?
Monitor closely with scheduled imaging (every six weeks in the trials), educate patients on ILD symptoms, and balance the risk with potentially improved disease control, adjusting treatment if ILD signs emerge while striving to preserve the curative intent.
Changing the Paradigm in HER2-Positive Early Breast Cancer
Q: What are the key considerations when choosing between DB11 and DB05 for a high-risk patient, and how do FDA approvals influence that decision?
Choose between regimens by considering risk profile, residual disease, tolerability, and long-term outcomes like IDFS, with FDA broad approvals offering flexibility but requiring individualization based on patient factors and NCCN/clinical judgment.
Changing the Paradigm in HER2-Positive Early Breast Cancer
Q: How do you view the role of Destiny 11 in changing the neoadjuvant approach for high-risk HER2-positive breast cancer?
Destiny 11 introduces TDXD-based regimens that can outperform the standard ACTHP in path CR, supporting a shift toward regimens that may reduce anthracycline exposure while maintaining or improving response, thus enabling more tailored, risk-adapted therapy.
What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma
Q: How are centers deciding between bispecific antibodies, CAR T cells, and ADCs for patients in the early relapse setting?
Centers assess access to CAR T programs, patient suitability and disease burden, logistical capabilities for inpatient versus outpatient care, and the relative toxicity profiles. The goal often involves bridging to CAR T when possible, using bispecific antibodies for disease control and outpatient management, and reserving ADCs like belantamab mafodotin for appropriate cases while managing ocular toxicity risks.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

This show centers on practical oncology and hematology guidance, featuring clinicians, researchers, pharmacists, and patient advocates who dissect current and emerging therapies, diagnostic strategies, and real-world care pathways. Episodes frequently explore biomarker-driven treatment decisions, sequencing of therapies, management of toxicities, and how new data translates into frontline and advanced-stage care. A recurring strength is the blend of academic expertise from major centers with real-world perspectives on outpatient administration, access to therapies, and multidisciplinary care, often framed by practical case discussions and healthcare system considerations. The format tends to emphasize actionable insights for clinicians, APP... more

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. Two Onc Docs
2. JAMA Medical News
3. OncLive® On Air
4. JAMA Clinical Reviews
5. NEJM This Week

How many episodes of this podcast are there?

this podcast launched 6 years ago and published 265 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Daniela Roman
2. Jordan Hill
3. Emanuela Palmerini
4. William Tack
5. James Davis
6. Kelley L. Julian
7. Gilles Salles
8. Pier Luigi Zinzani

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days